Researchers at Brigham and Women’s Hospital, Harvard Medical School demonstrate the utility of a blood-based panel for identifying Interstitial Lung Disease (ILD) in Rheumatoid Arthritis (RA) patients. The comorbidity of RA-ILD is prevalent and is associated with negative patient outcomes: ILD is the second leading cause of death in patients with RA. When combined with existing clinical risk factors, the biomarker panel (MMP7, PARC and SP-D) has considerable potential as an early diagnostic, which could improve clinical outcomes in patients with RA-ILD.

View Paper »